Pfizer Peer Comparison

NSE: PFIZER | BSE: 500680

₹3,842.20

₹-16.70 (-0.43%)

As on 05-Oct-2026 15:54IST

Market cap

₹17,544 Cr

Revenue (TTM)

₹2,570 Cr

P/E Ratio

23.9

P/B Ratio

Div. Yield

2 %

Edit

	Pfizer	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	17,544	20,338	19,915	16,514	14,818
Revenue (₹ Cr)	2,570	1,682	2,287	3,230	2,432
Net Profit (₹ Cr)	735.15	273.51	678.07	666.92	169.62
Net Margin (%)	26.88	16.19	28.10	20.60	6.90
RoE (%)	19.16	11.15	19.73	18.75	20.76
Price to Earnings	23.86	68.40	29.93	25.65	87.36
Price-To-Book	3.98	7.57	5.42	4.10	16.39

Income Statement (₹ Cr)

	Pfizer	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	2,519.65	1,538.87	2,187.19	3,129.42	2,275.58
Total Income	2,707.60	1,602.52	2,302.73	3,147.87	2,304.07
Total Expenditure	1,615.47	1,157.98	1,426.34	2,020.01	2,013.55
EBITDA	904.18	380.89	760.85	1,109.41	262.03
Depreciation	57.73	119.72	72.77	279.50	28.58
EBIT	846.45	261.17	688.08	829.91	233.45
Interest	9.57	58.79	0.87	192.67	4.49
Other Income	187.95	63.65	115.54	18.45	28.49
Exceptional Items	-49.16	12.16	--	-17.24	-5.25
Profit before Tax	975.67	295.31	802.79	638.54	252.20
Provision for Tax	253.24	51.98	153.06	-8.97	64.68
Profit after Tax	722.43	243.33	649.73	647.51	187.52

	Pfizer	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	4,202.90	2,591.20	3,586.42	3,902.67	872.79
Minority Interest	--	1.04	44.38	-7.01	--
Non-Current Liabilities	19.19	249.46	20.75	1,149.84	394.49
Current Liabilities	627.48	848.06	385.96	2,201.22	1,109.50
Total Liabilities	4,921.88	3,705.61	4,037.51	7,246.72	2,414.58

	Pfizer	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	1,046.35	2,578.95	1,451.85	5,582.75	509.16
Current Assets	3,803.22	1,109.77	2,585.66	1,663.97	1,859.88
Total Assets	4,921.88	3,705.61	4,037.51	7,246.72	2,414.58
Total Debt*	2.50	657.97	0.57	2,309.68	0.00
Net Current Assets	3,175.74	261.71	2,199.70	-537.25	750.38
Contingent Liabilities	370.49	160.01	17.53	51.57	121.23

	Pfizer	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	967.57	342.18	523.24	537.99	-15.14
Cash Flow from Investing Activities	-561.67	-325.92	-582.30	-369.46	18.69
Cash from Financing Activities	-798.31	13.62	-46.46	-313.53	-91.97
Net Cash Inflow / Outflow	-392.41	29.88	-105.52	-145.00	-88.42

	Pfizer	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	23.39	11.43	24.97	14.47	31.24
ROE (%)	17.16	9.82	20.79	19.23	23.02
ROA (%)	14.91	6.97	17.94	9.18	8.90
EBIT Margin (%)	43.34	28.89	40.07	36.04	12.77
Net Margin (%)	26.68	15.18	28.22	20.57	8.14
Cash Profit Margin (%)	29.72	23.59	33.03	28.49	9.47

	Pfizer	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	10.45	19.62	12.89	8.15	32.59
EBIT Growth (%)	19.68	29.72	17.90	8.91	-1.38
Net Profit Growth (%)	-5.88	210.81	20.08	72.82	62.02
EPS Growth (%)	-5.88	210.80	19.57	73.16	62.02
Book Value Growth (%)	-0.34	9.67	26.75	36.71	13.51

	Pfizer	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	29.89	28.03	17.84	29.02	103.45
Price / Book Value	5.14	2.63	3.27	4.62	22.39
Dividend Yield (%)	1.59	0.17	0.53	0.00	0.46
EV/EBITDA	16.93	16.72	12.43	17.93	65.23
Market Cap (₹ Cr)	21,592.90	6,819.66	11,439.22	17,980.08	19,398.64

	Pfizer	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.00	0.25	0.00	0.59	0.00
Short term debt to equity ratio	0.00	0.16	0.00	0.12	--
Current Ratio	6.06	1.31	6.70	0.76	1.68
Quick Ratio	5.31	0.88	5.59	0.56	0.75
Interest Coverage	102.95	6.02	923.75	4.31	57.17

	Pfizer	Shilpa Medicare	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	7.22	33.72	37.76	21.74	9.39
Asset Turnover	0.54	0.44	0.60	0.46	1.08
Receivable days	26.06	113.81	121.68	63.88	31.88
Inventory Days	65.95	84.76	63.83	43.27	126.03
Payable days	81.01	101.94	108.28	151.85	163.79
Cash Conversion Cycle	11.00	96.62	77.23	-44.70	-5.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.